SABS News and Press, SAB Biotherapeutics Inc. From 12/16/21

SAB Biotherapeutics (NASDAQ:SABS) soars 19% premarket after announcing data, demonstrating that SAB-185, a therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The res...

FDA laboratory testing confirms SAB-185 neutralizes Omicron and other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue to show broad neutralization to viral variants SAB-185 ...

SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. The Company's Tc Bovine-based DiversitAb platform has presented two PoCs in the past two months. The Company’s developmen...

SAB Biotherapeutics Inc. (NASDAQ:SABS) traded today at a new 52-week high of $12.03. This new high was reached on approximately average trading volume as 393,000 shares traded hands, while the average 30-day volume is approximately 502,000 shares. SAB Biotherapeutics Inc. (NASDAQ:SABS) i...

SAB Biotherapeutics (NASDAQ:SABS) announced that its Phase 2a challenge study for experimental seasonal influenza therapy SAB-176 met the primary endpoint with statistical significance. However, the shares have lost ~2.5% in the pre-market. In the placebo-controlled study initiated ...

Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by DiversitAb™ platform in past two months Positive clinical results con...

Gainers: iSpecimen (NASDAQ:ISPC) +115%. Biofrontera (NASDAQ:BFRI) +68%. Allied Healthcare Products (NASDAQ:AHPI) +56%. NRx Pharmaceuticals (NASDAQ:NRXP) +52%. Adagio (NASDAQ:ADGI) +31%. Alpha Pro Tech (NYSE:APT) +23%. 180 Life Sciences (NASDAQ:ATNF) +20%. Moderna (NASDAQ:MRNA) +22%. SAB Bioth...

SAB Biotherapeutics (NASDAQ:SABS): 9M Net Loss $5.6M Cash and cash equivalents on September 30, 2021 were $10.8M as compared to $13.5M as of September 30, 2020. Press Release For further details see: SAB Biotherapeutics reports 9M results

Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis Awarded additional $60.5 million from DoD in expanded scope for advancement of SAB-185 Strengthened leadership team through app...

SAB Biotherapeutics Inc. (NASDAQ:SABS) traded at a new 52-week high today of $11.75. This new high was reached on approximately average trading volume as 393,000 shares traded hands, while the average 30-day volume is approximately 415,000 shares. There is potential upside of 15.3% for s...